SANTA CLARA, Calif. - HeartBeam, Inc. (NASDAQ:BEAT), a company specializing in medical technology for cardiac care, has announced the acquisition of two new patents from the United States Patent and Trademark Office. These additions bring the company's portfolio to 14 US and 4 international patents for its vectorelectrocardiography (VECG) technology. This technology captures three-dimensional signals of the heart and translates them into 12-lead electrocardiograms (ECGs).
The newly patented VECG technology is intended for use with compact, user-friendly devices, such as a credit-card-sized system, an extended wear patch, or a wristwatch. These devices are designed to enable physicians to monitor patients' cardiac health remotely.
One of the patents, titled "Mobile three-lead cardiac monitoring device and method for automated diagnostics," addresses the automated detection of heart attacks or Acute Myocardial Infarction (AMI) by comparing cardiac signals over time.
HeartBeam's method involves providing a comparative baseline ECG for each patient, which may help physicians in obtaining more detailed insights into a patient's cardiac health. This approach has been validated by a study published in JACC: Advances, which showed a significant improvement in diagnostic accuracy using HeartBeam's VECG method compared to a traditional 12-lead ECG.
The second patent, "Apparatus for generating an electrocardiogram," relates to HeartBeam's wrist-based ECG system. This is the second patent for the company's watch concept, which is designed to continuously monitor ECG and provide a high sensitivity 12-lead ECG from a single wrist-worn device.
In addition to these patents, HeartBeam has 20 pending patent applications worldwide. The patents and applications cover the fundamental aspects of HeartBeam's VECG technology and its various applications across the company's product line, which includes portable devices, continuous monitors, extended wear patches, and watch-based 12-lead ECGs.
The information for this article is based on a press release statement from HeartBeam, Inc. The company, listed on NASDAQ under the ticker BEAT, is committed to redefining the management of cardiac health through the development and protection of its VECG technology and product pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.